Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Profound Medical (PROF) Cash from Financing Activities (2023 - 2025)

Historic Cash from Financing Activities for Profound Medical (PROF) over the last 3 years, with Q1 2025 value amounting to -$290000.0.

  • Profound Medical's Cash from Financing Activities fell 10141.77% to -$290000.0 in Q1 2025 from the same period last year, while for Sep 2025 it was $35.1 million, marking a year-over-year increase of 8437.2%. This contributed to the annual value of $54.7 million for FY2024, which is 301480.64% up from last year.
  • As of Q1 2025, Profound Medical's Cash from Financing Activities stood at -$290000.0, which was down 10141.77% from $35.4 million recorded in Q4 2024.
  • In the past 5 years, Profound Medical's Cash from Financing Activities ranged from a high of $35.4 million in Q4 2024 and a low of -$603000.0 during Q2 2024
  • Moreover, its 3-year median value for Cash from Financing Activities was -$194000.0 (2023), whereas its average is $7.0 million.
  • The largest annual percentage gain for Profound Medical's Cash from Financing Activities in the last 5 years was 1790653.27% (2024), contrasted with its biggest fall of 21322.75% (2024).
  • Quarter analysis of 3 years shows Profound Medical's Cash from Financing Activities stood at -$199000.0 in 2023, then surged by 17906.53% to $35.4 million in 2024, then crashed by 100.82% to -$290000.0 in 2025.
  • Its Cash from Financing Activities was -$290000.0 in Q1 2025, compared to $35.4 million in Q4 2024 and -$592000.0 in Q3 2024.